Belt-Tightening Biogen Looks To Narrow Therapeutic Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Rising Tecfidera sales not enough to offset perceived need for 11% staff cut and pruning of the pipeline, CEO states.